NCT01217021View on ClinicalTrials.gov

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Alzheimer Disease

Interventions

DRUG

[18F] MNI-558

Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.

Trial Locations (1)

06510

Institute for Neurodegenerative Disorders, New Haven

Sponsors

Collaborators (1)

Molecular NeuroImaging

All Listed Sponsors

collaborator

Molecular NeuroImaging

OTHER

lead

Institute for Neurodegenerative Disorders

OTHER